Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape-Reference-Cited by-同舟云学术

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Published:2018-02-01 Issue:3 Volume:7 Page:135-146
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Nijsen Marjoleen J.M.A.¹,Wu Fan²,Bansal Loveleena³,Bradshaw-Pierce Erica⁴,Chan Jason R.⁵,Liederer Bianca M.⁶,Mettetal Jerome T.⁷,Schroeder Patricia⁸,Schuck Edgar⁹,Tsai Alice¹⁰,Xu Christine¹¹,Chimalakonda Anjaneya¹²,Le Kha¹³,Penney Mark¹⁴,Topp Brian¹⁵,Yamada Akihiro¹⁶,Spilker Mary E.¹⁷

Affiliation:

1. Abbvie Inc; North Chicago Illinois USA

2. Novartis Institutes for Biomedical Research; East Hanover New Jersey USA

3. GlaxoSmithKline; King of Prussia Philadelphia USA

4. Takeda; San Diego California USA

5. Eli Lilly and Company; Indianapolis Indiana USA

6. Genentech Inc.; South San Francisco California USA

7. AstraZeneca, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca; Boston Massachusetts USA

8. Biogen; Cambridge Massachusetts USA

9. Eisai Inc; Woodcliff Lake New Jersey USA

10. Vertex Pharmaceuticals Incorporated; Boston Massachusetts USA

11. Sanofi; Bridgewater New jersey USA

12. Bristol-Myers Squibb; Princeton New Jersey USA

13. Agios; Boston Massachusetts USA

14. UCB; Celltech, Slough Berkshire United Kingdom

15. Merck & Co., Inc; Kenilworth New Jersey USA

16. Astellas Pharma Inc.; Tokyo Japan

17. Pfizer Worldwide Research and Development; San Diego California USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Reference30 articles.

1. Innovation in the pharmaceutical industry: new estimates of R&D costs;DiMasi;J. Health Econ.,2016

2. Diagnosing the decline in pharmaceutical R&D efficiency;Scannell;Nat. Rev. Drug Discov.,2012

3. Trial watch: phase II and phase III attrition rates 2011-2012;Arrowsmith;Nat. Rev. Drug Discov.,2013

4. Trends in clinical success rates;Smietana;Nat. Rev. Drug Discov.,2016

5. U.S. Department of Health and Human Services https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM113411.pdf 2004

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Digital patient twins for personalized therapeutics and pharmaceutical manufacturing;Frontiers in Digital Health;2024-01-05

2. Passive Immunotherapies Targeting Amyloid-βin Alzheimer’s Disease: A Quantitative Systems Pharmacology Perspective;Molecular Pharmacology;2023-10-31

3. Glycolysis in Chronic Liver Diseases: Mechanistic Insights and Therapeutic Opportunities;Cells;2023-07-26

4. Application of Quantitative Systems Pharmacology to Pediatric Drug Safety Assessment;Clinical Pharmacology & Therapeutics;2023-07-14

5. Quantitative systems modeling approaches towards model-informed drug development: Perspective through case studies;Frontiers in Systems Biology;2023-01-12